Wagner v. Novartis Pharmaceuticals Corp.

565 F. Supp. 2d 940, 2008 U.S. Dist. LEXIS 52974, 2008 WL 2713712
CourtDistrict Court, E.D. Tennessee
DecidedJuly 10, 2008
Docket1:07-cr-00129
StatusPublished
Cited by5 cases

This text of 565 F. Supp. 2d 940 (Wagner v. Novartis Pharmaceuticals Corp.) is published on Counsel Stack Legal Research, covering District Court, E.D. Tennessee primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Wagner v. Novartis Pharmaceuticals Corp., 565 F. Supp. 2d 940, 2008 U.S. Dist. LEXIS 52974, 2008 WL 2713712 (E.D. Tenn. 2008).

Opinion

MEMORANDUM AND ORDER

H. BRUCE GUYTON, United States Magistrate Judge.

This case is before the undersigned pursuant to 28 U.S.C. § 636(c), Rule 73(b) of the Federal Rules of Civil Procedure, and the consent of the parties, for all further proceedings, including entry of judgment [Doc. 6], on the defendant’s Motion for Summary Judgment. [Doc. 46] The parties appeared before the Court on July 7, 2008, for a hearing on the instant motion. Attorneys James K. Scott, Anne Lamkin Durward, and Cynthia Wilkinson appeared on behalf of the plaintiff, and attorneys Lawrence L. Summers, Aaron R. Gelb, and Patty K. Wheeler appeared on behalf of the defendant. After the hearing, the Court took the motion under advisement, and it is now ripe for adjudication. For the reasons set forth below, the defendant’s motion [Doc. 46] will be GRANTED in part and DENIED in part.

I. Relevant Facts

In 1991, plaintiff Robert Wagner (‘Wagner”) was hired by Ciba-Geigy, defendant Novartis Pharmaceuticals Corporation’s (“Novartis”) predecessor, as a sales professional. In 1992, Wagner advanced to the position of Medical Representative. In 1995, Wagner was promoted to Senior Medical Representative, and then promot *943 ed again to Institutional Specialist. On May 9, 1998, Wagner began his service with the Air Force Reserve.

In 2000, Wagner was promoted to Senior Health Systems Specialist. In 2001, Wagner became a Veterans Affairs Specialist. In 2002, Wagner received the Cornerstone Club Award, a prestigious sales award at Novartis. Wagner also received the President’s Club Award and the MVP award. Sometime in early 2002, Wagner attended Management Development-1 (“MD-1”), the first in a three part training course used by Novartis to train employees for management positions in the company. In May, 2002, Wagner applied for the position of Area Sales Manager in the Veteran’s Affairs Specialty Field. Wagner did not receive an interview and was not selected for the position.

In February, 2003, Wagner attended and failed MD-2. In 2004, Wagner became a Senior Hospital Specialist, and then became a Pioneering Member of the Eastern Hospital Specialists Council. In July, 2004, Wagner applied for a District Manager position in Knoxville, Tennessee, but was not interviewed and was not selected for the position. In January, 2005, Wagner, applied for another District Manger position in Knoxville, but was not interviewed and was not selected. In March, 2005, Wagner successfully completed MD-2. In August,2005, Wagner successfully completed MD-3.

On September 15, 2005, Wagner applied for a District Manager position in San Antonio, Texas. Wagner was not interviewed for this position and was not selected. In October, 2005, Wagner applied for a District Manager position in Seattle, Washington. Wagner was not interviewed for this position and was not selected. In November, 2005, Wagner applied for an Area Sales Manager position in Tampa, Florida. Wagner was not interviewed for the position and was not selected.

In December, 2005, Wagner was offered a management position with Sanofi-Aven-tis, a competitor of Novartis. On January 3, 2006, Wagner submitted a letter of resignation to Novartis. January 31, 2006, was Wagner’s last day of employment with Novartis. On February 1, 2006, Wagner began work with Sanofi-Aventis. On April 11, 2007, Wagner filed the instant suit, alleging that Novartis discriminated against him by failing to promote him, by retaliating against him for protected activities, and by constructively discharging him, all in violation of the Uniformed Services Employment and Re-employment Rights Act (“USERRA”), 38 U.S.C. § 4301, et seq. Wagner further alleges that Novartis’ actions violated Tennessee common law and the Tennessee Public Protection Act, Tenn.Code. Ann. § 50-1-304.

II. Standard of Review

Under Fed.R.Civ.P. 56(c), summary judgment is proper if “the pleadings, depositions, answers to interrogatories, admissions on file, together with the affidavits, if any, show that there is no genuine issue of material fact and that the moving party is entitled to judgment as a matter of law.” The burden of establishing there is no genuine issue of material fact lies upon the moving party. Celotex Corp. v. Catrett, 477 U.S. 317, 330 n. 2, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986). The court must view the facts and all inferences to be drawn therefrom in the light most favorable to the non-moving party. Matsushita Elec. Indus. Co. v. Zenith Radio Corp., 475 U.S. 574, 587, 106 S.Ct. 1348, 89 L.Ed.2d 538 (1986). To establish a genuine issue as to the existence of a particular element, the non-moving party must point to evidence in the record upon which a reasonable jury *944 could find in its favor. Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986). The genuine issue must also be material; that is, it must involve facts that might affect the outcome of the suit under the governing law. Id.

The judge’s function at the point of summary judgment is limited to determining whether sufficient evidence has been presented to make the issue of fact a proper jury question, and not to weigh the evidence, judge the credibility of witnesses, or determine the truth of the matter. Id. at 249, 106 S.Ct. 2505. Thus, “[t]he inquiry performed is the threshold inquiry of determining whether there is the need for trial — whether, in other words, there are any genuine factual issues that properly can be resolved only by a finder of fact because they may reasonably be resolved in favor of either party.” Id. at 250, 106 S.Ct. 2505.

III. Positions of the Parties

Novartis seeks summary judgment in its favor as to all of Wagner’s claims, arguing that the four year statute of limitations bars some of Wagner’s claims, that Wagner’s military service was not a motivating factor in any of the employment decisions made by Novartis, that Novartis did not discriminate or retaliate against Wagner, and that Wagner was not terminated or constructively discharged. Wagner opposes the motion, arguing that there is no statute of limitations for USERRA claims, and further arguing that there are genuine issues of material fact as to each of his claims, and thus summary judgment is not appropriate.

IV. Analysis

A. Statute of Limitations

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Middleton v. City of Chicago
578 F.3d 655 (Seventh Circuit, 2009)
Hogan v. United Parcel Service
648 F. Supp. 2d 1128 (W.D. Missouri, 2009)
Potts v. Howard University Hospital
623 F. Supp. 2d 68 (District of Columbia, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
565 F. Supp. 2d 940, 2008 U.S. Dist. LEXIS 52974, 2008 WL 2713712, Counsel Stack Legal Research, https://law.counselstack.com/opinion/wagner-v-novartis-pharmaceuticals-corp-tned-2008.